Gossamer Bio (GOSS) Revenue (2024 - 2026)

Gossamer Bio has reported Revenue for 3 years, with the latest figure at $9.2 million in Q2 2026.

• On a quarterly basis, Revenue fell 19.59% year-over-year to $9.2 million in Q2 2026; TTM through Jun 2026 was $53.3 million, a 32.43% increase from a year earlier, with the FY2025 full-year figure at $48.5 million, down 57.74% from the prior year.
• Revenue was $9.2 million for Q2 2026 at Gossamer Bio, down from $17.0 million in the prior quarter.
• The five-year high for Revenue was $95.8 million in Q2 2024, with the low at $9.2 million in Q2 2026.
• Average Revenue over 3 years is $21.0 million, with a median of $11.5 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Revenue tumbled 88.01% in 2025, then jumped 71.45% in 2026.
• Over 3 years, Revenue stood at $9.4 million in 2024, then soared by 47.13% to $13.8 million in 2025, then sank by 33.05% to $9.2 million in 2026.
• The last three Revenue figures came in at $9.2 million (Q2 2026), $17.0 million (Q1 2026), and $13.8 million (Q4 2025), per Business Quant data.